Admedus is developing a range of therapeutic vaccines through our investment in the Research & Development of immunotherapies based on Professor Ian Frazer’s next-generation vaccine technology.
Our scientific team is developing a suite of vaccines that treat and prevent infectious diseases and cancers caused by Herpes Simplex Virus and Human Papillomavirus (HPV).
Admedus recently announced that the HPV therapeutic vaccine has progressed well in preclinical studies. Our company will now advance the programme into a Phase Ib study.
The unique delivery mechanism of our vaccine ensures that there is a stronger and more effective immune response creating both a therapeutic (treat) and prophylactic (prevent) effect.
Admedus is focused on commercialising a new era of therapeutic vaccines.